Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
3.110
-0.110 (-3.42%)
At close: Nov 13, 2026, 4:00 PM EST
2.950
-0.160 (-5.14%)
Pre-market: Nov 16, 2026, 7:29 AM EST
Entera Bio Employees
Entera Bio had 27 employees as of September 30, 2026. The number of employees increased by 5 or 22.73% compared to the same quarter last year. That makes Entera Bio the 37,503rd largest employer in the world and 5,238th in the United States.
Employees
27
Change (1Y)
5
Growth (1Y)
22.73%
Revenue / Employee
n/a
Profits / Employee
-$1,090,000
Market Cap
541.57M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2026 | 27 | 5 | 22.73% | 27 | 0 |
| Jun 30, 2026 | 22 | 1 | 4.76% | 20 | 2 |
| Mar 31, 2026 | 22 | 2 | 10.00% | 20 | 2 |
| Dec 31, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Sep 30, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Jun 30, 2025 | 21 | 2 | 10.53% | 19 | 2 |
| Mar 31, 2025 | 20 | 1 | 5.26% | 18 | 2 |
| Dec 31, 2024 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2024 | 20 | -1 | -4.76% | 18 | 2 |
| Jun 30, 2024 | 19 | -2 | -9.52% | 17 | 2 |
| Mar 31, 2024 | 19 | 1 | 5.56% | 17 | 2 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Sep 30, 2023 | 21 | 2 | 10.53% | 19 | 2 |
| Jun 30, 2023 | 21 | -1 | -4.55% | 19 | 2 |
| Mar 31, 2023 | 18 | -3 | -14.29% | 18 | 0 |
| Dec 31, 2022 | 17 | -3 | -15.00% | 15 | 2 |
| Sep 30, 2022 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Mar 31, 2022 | 21 | 2 | 10.53% | 21 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| REGENXBIO | 371 |
| Capricor Therapeutics | 231 |
| Neurogene | 131 |
| Orchestra BioMed Holdings | 86 |
| Zevra Therapeutics | 61 |
| Eupraxia Pharmaceuticals | 49 |
| Surrozen | 44 |
ENTX News
- 6 days ago - Entera Bio Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - Entera Announces Third Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 10 days ago - Entera Bio Quarterly report: Q3 2026 - Filings
- 10 days ago - Entera Bio Earnings release: Q3 2026 - Filings
- 20 days ago - Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors - GlobeNewsWire
- 4 weeks ago - Entera Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting - GlobeNewsWire